Eptifibatide-induced thrombocytopenia.
J Thromb Thrombolysis
; 25(2): 204-6, 2008 Apr.
Article
de En
| MEDLINE
| ID: mdl-18008040
ABSTRACT
Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-year-old man presenting with a non ST-elevation myocardial infarction (NSTEMI) who underwent primary PCI with stenting and developed stent thrombosis 5 days after the procedure. He underwent repeat PCI with readministration of eptifibatide and subsequently developed profound thrombocytopenia within 4 h. This report adds another case of eptifibatide associated thrombocytopenia to the literature and reinforces the importance of platelet count monitoring after therapy with this agent.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Peptides
/
Thrombopénie
/
Antiagrégants plaquettaires
Limites:
Adult
/
Humans
/
Male
Langue:
En
Journal:
J Thromb Thrombolysis
Sujet du journal:
ANGIOLOGIA
Année:
2008
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique